X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further systemic damage.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Serb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2021
Details:
Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Megludase
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ohara Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Serb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 02, 2021
Details:
An ongoing arm of the study triggered by the difficult circumstances created by the COVID-19 pandemic is exploring the planned use of Voraxaze® (glucarpidase) to enable high dose MTX treatment of CNSL on an outpatient basis.
Lead Product(s): Glucarpidase,Methotrexate
Therapeutic Area: Neurology Product Name: Voraxaze
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
In this study, adult patients with isolated CNSL are treated with rituximab and methotrexate administered for eight cycles. Voraxaze® is given 24 hours following start of each methotrexate infusion.
Lead Product(s): Glucarpidase,Methotrexate,Rituximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Agreement is executed between the parties for exclusive worldwide license of CoVaccine HT from BTG Specialty Pharmaceuticals, for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu.
Lead Product(s): CoVaccine HT
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Soligenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
